- Home
- RVMD vs PEG Comparison
RVMD vs PEG Comparison
Compare RVMD & PEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVMD | PEG |
|---|---|---|
| Founded | 2014 | 1903 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Power Generation |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3B | 37.0B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | RVMD | PEG |
|---|---|---|
| Price | $183.99 | $72.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 25 | 23 |
| Target Price | ★ $258.84 | $81.32 |
| AVG Volume (30 Days) | 1.9M | ★ 3.3M |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | N/A | ★ 3.66% |
| EPS Growth | N/A | ★ 19.21 |
| EPS | N/A | ★ 2.15 |
| Revenue | N/A | ★ $12,168,000,000.00 |
| Revenue This Year | N/A | $1.22 |
| Revenue Next Year | $526.64 | $7.95 |
| P/E Ratio | ★ N/A | $34.06 |
| Revenue Growth | N/A | ★ 18.25 |
| 52 Week Low | $58.91 | $66.15 |
| 52 Week High | $224.31 | $87.63 |
Technical Indicators
Market Signals| Indicator | RVMD | PEG |
|---|---|---|
| Relative Strength Index (RSI) | 56.58 | 56.98 |
| Support Level | $198.91 | $72.53 |
| Resistance Level | $207.50 | $74.65 |
| Average True Range (ATR) | 8.24 | 1.20 |
| MACD | 1.42 | 0.23 |
| Stochastic Oscillator | 86.26 | 72.67 |
Price Performance
Historical ComparisonAbout RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
About PEG Public Service Enterprise Group Incorporated
Public Service Enterprise Group is the holding company for a regulated utility (PSE&G) and PSEG Power, which owns all or a share of three nuclear plants and clean energy projects. PSE&G provides regulated gas and electricity delivery services in New Jersey to a combined 4.3 million customers. Public Service Enterprise Group also operates the Long Island Power Authority system under a contract extension through 2030. In 2022, the company sold its gas and oil power plants in the mid-Atlantic, New York, and the Northeast.